BC Week In Review | Jan 6, 2014
Clinical News

Otlertuzumab: Interim Phase Ib/II data

Interim data from 60 evaluable patients with relapsed CLL who failed 1-3 prior treatments in the Phase II portion of the open-label, U.S. Phase Ib/II Study 16201 showed that 20 mg/kg IV otlertuzumab given weekly...
BC Week In Review | Jan 6, 2014
Clinical News

Otlertuzumab: Interim Phase Ib data

Interim data from 20 evaluable previously untreated CLL patients in the first cohort of the open-label, U.S. Phase Ib Study 16009 showed that a single 10 mg/kg dose of IV otlertuzumab followed by once-weekly doses...
BC Week In Review | May 13, 2013
Clinical News

TRU-016: Completed Phase Ib/II enrollment

Emergent completed enrollment of about 60 patients who have failed up to 3 previous treatments in the Phase II portion of the open-label, U.S. Phase Ib/II Study 16201 of IV TRU-016 given in 28-day cycles....
BC Week In Review | Apr 15, 2013
Clinical News

TRU-016: Phase Ib amended

Emergent amended an open-label, U.S. Phase Ib trial evaluating IV TRU-016 given weekly for 8 weeks followed by 4 monthly doses plus rituximab to include 2 additional cohorts of 16 patients each. Patients in the...
BC Week In Review | Jan 7, 2013
Clinical News

TRU-016 regulatory update

Emergent said the European Commission granted Orphan Drug designation for TRU-016 to treat chronic lymphocytic leukemia (CLL). The humanized small modular immunopharmaceutical (SMIP) that targets the CD37 antigen has Orphan Drug designation in the U.S....
BC Week In Review | Nov 12, 2012
Clinical News

TRU-016: Phase Ib/II data

Top-line data from 12 patients in the open-label Phase Ib portion of a Phase Ib/II trial showed that 15 and 20 mg/kg TRU-016 plus Treanda bendamustine each produced 2 complete responses. The best ORR at...
BC Week In Review | Nov 5, 2012
Clinical News

TRU-016: Phase Ib started

Emergent began an open-label, U.S. Phase Ib trial to evaluate IV TRU-016 given weekly for 8 weeks followed by 4 monthly doses plus rituximab in about 24 previously untreated patients. Patients will receive 10 mg/kg...
BC Week In Review | May 14, 2012
Company News

Emergent BioSolutions, Pfizer deal

Emergent said in a SEC filing that Pfizer notified the company of plans to terminate a 2006 deal granting the pharma worldwide rights to develop and commercialize small modular immunopharmaceutical (SMIP) therapeutics that bind to...
BC Week In Review | Jan 2, 2012
Company News

Emergent BioSolutions, Abbott deal

Emergent said Abbott will terminate a 2009 deal to co-develop and commercialize Emergent's cancer product TRU-016 . Abbott's decision is a result of a portfolio prioritization process, according to Emergent. Until the termination becomes effective on...
BC Week In Review | Jan 2, 2012
Clinical News

TRU-016: Phase II started

Emergent began the Phase II portion of an open-label, U.S. Phase Ib/II trial of IV TRU-016 given in 28-day cycles in patients who have failed up to 3 previous treatments. The Phase II portion will...
Items per page:
1 - 10 of 117
BC Week In Review | Jan 6, 2014
Clinical News

Otlertuzumab: Interim Phase Ib/II data

Interim data from 60 evaluable patients with relapsed CLL who failed 1-3 prior treatments in the Phase II portion of the open-label, U.S. Phase Ib/II Study 16201 showed that 20 mg/kg IV otlertuzumab given weekly...
BC Week In Review | Jan 6, 2014
Clinical News

Otlertuzumab: Interim Phase Ib data

Interim data from 20 evaluable previously untreated CLL patients in the first cohort of the open-label, U.S. Phase Ib Study 16009 showed that a single 10 mg/kg dose of IV otlertuzumab followed by once-weekly doses...
BC Week In Review | May 13, 2013
Clinical News

TRU-016: Completed Phase Ib/II enrollment

Emergent completed enrollment of about 60 patients who have failed up to 3 previous treatments in the Phase II portion of the open-label, U.S. Phase Ib/II Study 16201 of IV TRU-016 given in 28-day cycles....
BC Week In Review | Apr 15, 2013
Clinical News

TRU-016: Phase Ib amended

Emergent amended an open-label, U.S. Phase Ib trial evaluating IV TRU-016 given weekly for 8 weeks followed by 4 monthly doses plus rituximab to include 2 additional cohorts of 16 patients each. Patients in the...
BC Week In Review | Jan 7, 2013
Clinical News

TRU-016 regulatory update

Emergent said the European Commission granted Orphan Drug designation for TRU-016 to treat chronic lymphocytic leukemia (CLL). The humanized small modular immunopharmaceutical (SMIP) that targets the CD37 antigen has Orphan Drug designation in the U.S....
BC Week In Review | Nov 12, 2012
Clinical News

TRU-016: Phase Ib/II data

Top-line data from 12 patients in the open-label Phase Ib portion of a Phase Ib/II trial showed that 15 and 20 mg/kg TRU-016 plus Treanda bendamustine each produced 2 complete responses. The best ORR at...
BC Week In Review | Nov 5, 2012
Clinical News

TRU-016: Phase Ib started

Emergent began an open-label, U.S. Phase Ib trial to evaluate IV TRU-016 given weekly for 8 weeks followed by 4 monthly doses plus rituximab in about 24 previously untreated patients. Patients will receive 10 mg/kg...
BC Week In Review | May 14, 2012
Company News

Emergent BioSolutions, Pfizer deal

Emergent said in a SEC filing that Pfizer notified the company of plans to terminate a 2006 deal granting the pharma worldwide rights to develop and commercialize small modular immunopharmaceutical (SMIP) therapeutics that bind to...
BC Week In Review | Jan 2, 2012
Company News

Emergent BioSolutions, Abbott deal

Emergent said Abbott will terminate a 2009 deal to co-develop and commercialize Emergent's cancer product TRU-016 . Abbott's decision is a result of a portfolio prioritization process, according to Emergent. Until the termination becomes effective on...
BC Week In Review | Jan 2, 2012
Clinical News

TRU-016: Phase II started

Emergent began the Phase II portion of an open-label, U.S. Phase Ib/II trial of IV TRU-016 given in 28-day cycles in patients who have failed up to 3 previous treatments. The Phase II portion will...
Items per page:
1 - 10 of 117